2017
Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
Fong L, Small E, Petrylak D, Quinn D, Antonarakis E, Kibel A, Chang N, Kandadi H, Sheikh N, Drake C. Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC). Journal Of Clinical Oncology 2017, 35: 143-143. DOI: 10.1200/jco.2017.35.6_suppl.143.Peer-Reviewed Original ResearchMetastatic castration-resistant PCProstatic acid phosphataseProstate cancerIgG responsesDisease courseSymptomatic metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerAntigen-presenting cell activationCastration-resistant prostate cancerPeripheral blood mononuclear cellsAndrogen-dependent prostate cancerBlood mononuclear cellsCross-trial comparisonsCancer-related antigensGranulocyte-macrophage colony-stimulating factorMacrophage colony-stimulating factorColony-stimulating factorImproved OSAndrogen suppressionClinical benefitAutologous immunotherapyDisease stageMononuclear cellsAntibody responseClinical trials
2007
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Petrylak D. Risk Factors for the Development of Bone Metastases in Prostate Cancer. European Urology Open Science 2007, 6: 677-682. DOI: 10.1016/j.eursup.2007.03.005.Peer-Reviewed Original ResearchAndrogen deprivation therapyBone metastasesEarly prostate cancerProstate cancerRisk factorsEarly identificationDisease courseBone lossHigher baseline PSA levelsProstate-specific antigen levelChronic bone painHigh PSA velocityBaseline PSA levelsSpinal cord compressionMajority of patientsAdvanced prostate cancerBone health issuesBone health maintenanceBone mineral densityBone painCord compressionPalliative radiotherapyPSA velocitySkeletal complicationsPathologic fracture